RxSight 10-Q: Q3 Revenue Down 19% to $24.6M, $254.7M Cash, Alcon $50M Now Nonrefundable
RXST is trading near its 52-week low of $4.4 (11% below the low).
Summary
RxSight's Q3 10-Q confirms revenue down 19% to $24.6 million and a $16.2 million net loss, backed by $254.7 million in cash, with the $50 million Alcon upfront now nonrefundable and LDD manufacturing paused on excess inventory.
Key Events · Earnings and Guidance · RXST
-
Q3 Revenue Falls 19% to $24.6M
Total revenue of $24.6 million versus $30.3 million a year ago, driven by 23,128 LAL units and only 3 LDDs sold versus 25 in Q3 2025, reflecting competitive pressure.
-
Net Loss Widens to $16.2M
Net loss of $(16.2) million, or $(0.39) per share, versus $(9.8) million, or $(0.24) per share, a year ago; gross margin slipped to 73.6% from 79.9% on higher inventory reserves.
-
Alcon $50M Becomes Nonrefundable
The $50.0 million portion of the $60 million Alcon upfront payment lapsed its 120-day refund window on October 28, 2026 and will be added to the transaction price and allocated to performance obligations in Q4 2026.
-
Cash of $254.7M Funds 12 Months
Cash, cash equivalents and short-term investments totaled $254.7 million at September 30, 2026; management states existing resources fund operations for at least the next 12 months.
Analysis · RXST · Industrial Applications And Services
The 10-Q confirms the weak quarter already reported in the concurrent 8-K, but its real value is the balance-sheet detail: $254.7 million of cash and investments against a $16.2 million quarterly net loss, and the $50.0 million Alcon upfront payment became nonrefundable on October 28, 2026, removing a refund liability from the balance sheet and adding $50 million to Q4 revenue to be recognized. Against that, the core business is shrinking — revenue fell 19% on 23,128 LAL units and only 3 LDDs sold versus 25 a year ago — and the company paused LDD manufacturing because inventory exceeds near-term demand, with reserves rising $1.8 million in the quarter. Management also ran an impairment test on long-lived assets after the market-cap decline and concluded no write-down was needed, a judgment call that would change if the stock and LDD demand stay weak.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RXST was trading at $3.92 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $190.9M. The 52-week trading range was $4.40 to $13.22. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.